These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37271530)

  • 1. [Advances in the therapy for von Willebrand disease].
    Nakayama T
    Rinsho Ketsueki; 2023; 64(5):389-396. PubMed ID: 37271530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of von Willebrand factor (recombinant) therapy for adult patients living with severe type 3 von Willebrand disease.
    Hancock JM; Escobar MA
    Expert Rev Hematol; 2023 Mar; 16(3):157-161. PubMed ID: 36861346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant von Willebrand factor: a first-of-its-kind product for von Willebrand disease.
    Singal M; Kouides PA
    Drugs Today (Barc); 2016 Dec; 52(12):653-664. PubMed ID: 28276537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vonicog alfa for the management of von Willebrand disease: a comprehensive review and single-center experience.
    Tran T; Arnall J; Moore DC; Ward L; Palkimas S; Man L
    J Thromb Thrombolysis; 2020 Apr; 49(3):431-440. PubMed ID: 31902122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study).
    Lissitchkov TJ; Buevich E; Kuliczkowski K; Stasyshyn O; Cerqueira MH; Klukowska A; Joch C; Seifert W
    Blood Coagul Fibrinolysis; 2017 Mar; 28(2):152-162. PubMed ID: 27203734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Efficacy and Safety of Fanhdi
    Jiménez-Yuste V; Alvarez-Román MT; Palomo Bravo Á; Galmes BJ; Nieto Hernández MDM; Benítez Hidalgo O; Marzo Alonso C; Pérez González NF; Coll J; Núñez R; Carrasco M; García Candel F; Gonzalez-Porras JR; Hernández García C; Varó Castro MJ; Mir R
    Clin Appl Thromb Hemost; 2022; 28():10760296221074348. PubMed ID: 35108125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results.
    Leebeek FWG; Peyvandi F; Escobar M; Tiede A; Castaman G; Wang M; Wynn T; Baptista J; Wang Y; Zhang J; Mellgård B; Özen G
    Blood; 2022 Jul; 140(2):89-98. PubMed ID: 35439298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
    Franchini M; Rossetti G; Tagliaferri A; Pattacini C; Pozzoli D; Lippi G; Manzato F; Bertuzzo D; Gandini G
    Haematologica; 2003 Nov; 88(11):1279-83. PubMed ID: 14607757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U; Metzner HJ; Müller HG
    Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of von Willebrand disease.
    Rodeghiero F; Castaman G
    Semin Hematol; 2005 Jan; 42(1):29-35. PubMed ID: 15662613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with von Willebrand factor concentrate plus recombinant factor VIII during cesarean section in a patient with type 3 von Willebrand disease and a low inhibitor titer: a case report.
    Chikasawa Y; Hagiwara T; Bingo M; Amano K; Kikuchi S; Mitsuhashi A; Shinozawa K; Fukutake K; Kinai E
    Int J Hematol; 2022 Oct; 116(4):622-629. PubMed ID: 35532874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical efficacy and safety of the FVIII/VWF concentrate, BIOSTATE®, in children with von Willebrand disorder: a multi-centre retrospective review.
    Howman R; Barnes C; Curtin J; Price J; Robertson J; Russell S; Seldon M; Suppiah R; Teague L; Barrese G
    Haemophilia; 2011 May; 17(3):463-9. PubMed ID: 21118340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.
    Federici AB; Baudo F; Caracciolo C; Mancuso G; Mazzucconi MG; Musso R; Schinco PC; Targhetta R; Mannuccio Mannucci P
    Haemophilia; 2002 Nov; 8(6):761-7. PubMed ID: 12410644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haemate P/Humate-P for the treatment of von Willebrand disease: considerations for use and clinical experience.
    Auerswald G; Kreuz W
    Haemophilia; 2008 Nov; 14 Suppl 5():39-46. PubMed ID: 18786009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of replacement therapy for von Willebrand disease: From plasma fraction to recombinant von Willebrand factor.
    Peyvandi F; Kouides P; Turecek PL; Dow E; Berntorp E
    Blood Rev; 2019 Nov; 38():100572. PubMed ID: 31229334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diagnosis and management of von Willebrand disease].
    Higasa S; Tokugawa T; Sawada A
    Rinsho Ketsueki; 2018; 59(10):2222-2232. PubMed ID: 30305529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology, diagnosis, and management of von Willebrand disease in India.
    Ghosh K; Shetty S
    Semin Thromb Hemost; 2011 Jul; 37(5):595-601. PubMed ID: 22102205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.